VEGF has also been targeted by nanoparticles through the delivery of small interfering RNA (siRNA) to endometrial lesions in vitro and in vivo using RGD1-R6 nanoparticle carriers, reducing the size of endometriosis lesion by decreasing VEGFA expression and increasing anti-angiogenic effects [31]. This evidence concerns the gene VEGFA and endometriosis.